维生素A、B、C、D、E补充对ICU新冠肺炎患者改善与死亡率影响的随机对照试验方案结构化摘要
本研究为随机、单盲、两臂平行对照临床试验,计划纳入伊朗德黑兰Imam Khomeini医院综合ICU的60例COVID-19患者(每组30例),干预组接受7天维生素A、B、C、D、E补充,对照组不接受补充或安慰剂。主要结局包括肺部受累严重程度、呼吸支持、SpO2、炎症指标、住院时长和死亡率,旨在评估维生素补充对ICU患者病情严重程度和死亡率的影响。
要点
- 7天补充维生素A、B、C、D、E,对照组无安慰剂。
- 计划纳入60例ICU的COVID-19患者,每组30例。
- 主要观察死亡率、呼吸支持、SpO2及炎症指标等。
核心结论
- 该研究将验证维生素A、B、C、D、E补充能否显著改善ICU新冠肺炎患者的严重程度和死亡率。
研究设计与样本
- 随机、单盲、两臂(1:1比例)平行组临床试验。
- 在伊朗德黑兰Imam Khomeini医院综合ICU的COVID-19患者中开展。
- 计划纳入60例患者,每组30例,采用基于性别的区组随机化。
- 纳入标准:年龄20-60岁、男女均可、临床或PCR确诊、未参加其他临床试验、无肾或肝功能异常。
- 排除标准:HIV等特定罕见病毒感染、过去一个月内接受化疗。
关键数值与推荐
- 干预组:维生素A每日25,000 IU;维生素D 600,000 IU研究期间一次;维生素E每日两次300 IU;维生素C每日四次;B族维生素每日Soluvit。
- Soluvit成分:硝酸硫胺3.1 mg、磷酸核黄素钠4.9 mg(对应维生素B2 3.6 mg)、烟酰胺40 mg、盐酸吡哆醇4.9 mg(对应维生素B6 4.0 mg)、泛酸钠16.5 mg(对应泛酸15 mg)、抗坏血酸钠113 mg(对应维生素C 100 mg)、生物素60 μg、叶酸400 μg、氰钴胺5 μg。
- 对照组不接受任何补充剂或安慰剂。
- 主要结局包括体重、身高、BMI、CT肺部受累严重程度、呼吸支持(有创或无创)、SpO2百分比、血清WBC、CRP、ESR、IL6、IFN-G、TNF-α、体温、肺外器官受累、住院时长和死亡率。
临床怎么用
- 该方案处于试验阶段,结果尚未报告,暂不能提供临床用药推荐。
局限性
- 对照组无安慰剂且仅对患者设盲,ICU工作人员知晓分组。
- 样本量计划为60例,规模较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study will evaluate the main hypothesis that supplementation with vitamins A, B, C, D, and E significantly improves the severity and mortality rate in ICU patients with COVID-19. TRIAL DESIGN: This study is a randomized, single-blinded, two-arm (1:1 ratio) parallel group clinical trial. PARTICIPANTS: We are conducting this study in patients with COVID-19 admitted to intensive care units at the Imam Khomeini Hospital Complex in Tehran, Iran. The inclusion criteria are as follows: (1) aged between 20 and 60 years, (2) both male and female patients with COVID-19, (3) clinical or definitive diagnosis (using polymerase chain reaction (PCR) test), (4) patients have not participated in other clinical trials, and (5) no renal or hepatic abnormalities. The exclusion criteria are as follows: (1) patients with specific and rare viral diseases such as HIV and (2) patients who have been undergoing chemotherapy for the past month. INTERVENTION AND COMPARATOR: Duration of intervention: 7 days from randomization Intervention in the treatment group: Vitamin A 25,000 IU daily Vitamin D 600,000 IU once during study Vitamin E 300 IU twice daily Vitamin C is taken four times per day B vitamins are taken as a daily Soluvit [which included thiamine nitrate 3.1 mg, sodium riboflavin phosphate 4.9 mg (corresponding to vitamin B2 3.6 mg), nicotinamide 40 mg, pyridoxine hydrochloride 4.9 mg (corresponding to vitamin B6 4.0 mg), sodium pantothenate 16.5 mg (corresponding to pantothenic acid 15 mg), sodium ascorbate 113 mg (corresponding to vitamin C 100 mg), biotin 60 μg, folic acid 400 μg, and cyanocobalamin 5 μg] The control group will not receive any supplements or placebo. All supplements are made in Iran except for Soluvit (from Fresenius Kabi, New Zealand). MAIN OUTCOMES: 1. Weight, height, and BMI 2. Severity of pulmonary involvement according to CT scan 3. Respiratory support (invasive or non-invasive) 4. Percentage of oxygen saturation (SpO2 level) 5. Serum levels of WBC, CRP, ESR, IL6, IFN-G, and TNF-α 6. The patient's body temperature 7. The presence or absence of involvement of organs other than the lungs (e.g., heart, liver, kidneys) 8. Duration of hospitalization 9. Mortality rate RANDOMIZATION: At baseline, eligible patients were randomly assigned to a 1:1 ratio to one of two groups: intervention and control. Block randomization is used based on the gender of patients. BLINDING (MASKING): Patients are unaware of being placed in the intervention or control groups after signing consent. All treatment staff will be aware of which group each of the patients is in due to the specific conditions of the ICU and the absence of placebo for the control group. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): The researchers plan to include 60 patients in total, with 30 patients in each group. TRIAL STATUS: This is the first version of the protocol which started on April 2, 2020. Recruitment began April 2, 2020, and is expected to be complete by July 4, 2020. TRIAL REGISTRATION: The Iranian Registry of Clinical Trials IRCT20200319046819N1 . Registered on April 4, 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol (Fig. 1, Table 1).
引用
- Beigmohammadi MT, Bitarafan S, Hoseindokht A, et al. Impact of vitamins A, B, C, D, and E supplementation on improvement and mortality rate in ICU patients with coronavirus-19: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020. PMID: 32631405. doi:10.1186/s13063-020-04547-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。